Massachusetts Financial Services Co. MA decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 11.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,024,908 shares of the pharmaceutical company's stock after selling 263,590 shares during the quarter. Massachusetts Financial Services Co. MA owned 0.79% of Vertex Pharmaceuticals worth $981,716,000 at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of the business. Dakota Wealth Management raised its stake in Vertex Pharmaceuticals by 37.0% during the first quarter. Dakota Wealth Management now owns 10,147 shares of the pharmaceutical company's stock worth $4,919,000 after acquiring an additional 2,739 shares in the last quarter. Apollon Wealth Management LLC raised its stake in Vertex Pharmaceuticals by 106.4% during the first quarter. Apollon Wealth Management LLC now owns 25,127 shares of the pharmaceutical company's stock worth $12,182,000 after acquiring an additional 12,955 shares in the last quarter. Catalyst Financial Partners LLC raised its stake in Vertex Pharmaceuticals by 21.0% during the first quarter. Catalyst Financial Partners LLC now owns 1,361 shares of the pharmaceutical company's stock worth $660,000 after acquiring an additional 236 shares in the last quarter. Signaturefd LLC raised its stake in Vertex Pharmaceuticals by 13.0% during the first quarter. Signaturefd LLC now owns 5,705 shares of the pharmaceutical company's stock worth $2,766,000 after acquiring an additional 656 shares in the last quarter. Finally, Slow Capital Inc. raised its stake in Vertex Pharmaceuticals by 1.7% during the first quarter. Slow Capital Inc. now owns 11,834 shares of the pharmaceutical company's stock worth $5,737,000 after acquiring an additional 198 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.
Vertex Pharmaceuticals Trading Down 1.7%
NASDAQ:VRTX traded down $8.15 on Tuesday, reaching $464.20. 988,008 shares of the stock traded hands, compared to its average volume of 1,424,508. The firm has a market capitalization of $119.21 billion, a price-to-earnings ratio of -118.42 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a current ratio of 2.65, a quick ratio of 2.29 and a debt-to-equity ratio of 0.01. The company's 50 day moving average is $447.43 and its 200-day moving average is $461.58.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The business's quarterly revenue was up 2.6% compared to the same quarter last year. During the same period last year, the business earned $4.76 EPS. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts have commented on the company. Scotiabank lowered their target price on Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating for the company in a research note on Tuesday, May 6th. JPMorgan Chase & Co. upped their price objective on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an "overweight" rating in a research note on Monday. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Leerink Partnrs downgraded Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 6th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $535.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Fourteen equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $511.71.
Read Our Latest Report on Vertex Pharmaceuticals
Vertex Pharmaceuticals Company Profile
(
Free Report)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Featured Stories

Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.